Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
Go back to Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes| ADAMAS PHARMACEUT (NASDAQ: ADMS) | Delayed: 8.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.22 | 52 Week High | $31.84 | |||
| Open | $8.22 | 52 Week Low | $12.02 | |||
| Day High | $8.22 | P/E | N/A | |||
| Day Low | $8.22 | EPS | $0.00 | |||
| Volume | 10,391 | |||||
